# Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention

> **NCT07733934** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Antev Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Acute Urinary Retention
- Benign Prostate Hypertrophy(BPH)

## Interventions

- **DRUG:** Teverelix DP
- **DRUG:** Teverelix DP Placebo
- **DRUG:** Teverelix DP
- **DRUG:** Teverelix DP Placebo

## Key facts

- **NCT ID:** NCT07733934
- **Lead sponsor:** Antev Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-05
- **Final completion:** 2028-05
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733934, "Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*